These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2295931)

  • 1. Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine.
    Brown SJ; Slizofski WJ; Dadparvar S
    J Nucl Med; 1990 Jan; 31(1):115-7. PubMed ID: 2295931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of aluminum and gallium into tissues of the rat: influence of antibody against the transferrin receptor.
    Radunović A; Delves HT; Bradbury MW
    Biol Trace Elem Res; 1998; 62(1-2):51-64. PubMed ID: 9630424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gallium-67 citrate in liquid gastric emptying scintigraphy.
    Boyd SJ; Smart RC
    J Nucl Med; 1993 Sep; 34(9):1619-20. PubMed ID: 8355086
    [No Abstract]   [Full Text] [Related]  

  • 5. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 6. Al-toxicity studies in yeast using gallium as an aluminum analogue.
    Ritchie RJ; Raghupathi SS
    Biometals; 2008 Aug; 21(4):379-93. PubMed ID: 18058193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperaluminemia in renal failure: the influence of age and citrate intake.
    Bakir AA; Hryhorczuk DO; Ahmed S; Hessl SM; Levy PS; Spengler R; Dunea G
    Clin Nephrol; 1989 Jan; 31(1):40-4. PubMed ID: 2914409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 9. Altered biodistribution of Ga-67 citrate in an iron-overloaded patient with sickle cell disease.
    Loesberg AC; Martin WB
    Clin Nucl Med; 1994 Feb; 19(2):157-9. PubMed ID: 8187405
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute aluminemic encephalopathy in chronic renal failure: the citrate factor.
    Bakir AA
    Int J Artif Organs; 1989 Dec; 12(12):741-3. PubMed ID: 2613353
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful treatment of progressive dialysis encephalopathy. Case report].
    Weiland P; Köhler M; Glatzel E
    Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
    Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR
    Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk factors in aluminum toxicity in children with chronic renal failure.
    Santos F; Massie MD; Chan JC
    Nephron; 1986; 42(3):189-95. PubMed ID: 3511396
    [No Abstract]   [Full Text] [Related]  

  • 15. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 16. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gallium-67 scintigraphy in patients with hemochromatosis treated by deferoxamine.
    Nagamachi S; Hoshi H; Jinnouchi S; Ono S; Watanabe K
    Ann Nucl Med; 1988 May; 2(1):35-9. PubMed ID: 3275103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid aluminum levels following deferoxamine.
    Ellenberg R; King AL; Sica DA; Posner M; Savory J
    Am J Kidney Dis; 1990 Aug; 16(2):157-9. PubMed ID: 2382654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.